Warrant

A pre-revenue biotech with a $14.5M quarterly loss just raised capital through a private placement with three warrant series attached, and the mechanics tell a specific story about dilution, distress, and where tokenized equity is heading.

The May 21 8-K looks routine, but the separation of shares and warrants signals that a roughly $230 million acquisition hunt is now live and on the clock.